CD276 and cancer: Recent advancements in cancer immunotherapy have ushered in the era of immune checkpoint blockade, with newer targets such as CD47, LAG-3, TIM-3, TIGIT, and B7-H3 being explored in preclinical and clinical trials as potential therapeutic agents (Table 1).